Treatment options for triple-negative breast cancer with Ahmad Awada


In this video interview with Ahmad Awada from the Institut Jules Bordet (Belgium) find out about potential treatment options for triple-negative breast cancer such as eryaspase. Awada also describes what data has been obtained thus far from the TRYbeCA2 study, which is a Phase II proof-of-concept trial evaluating eryaspase in combination with gemcitabine and carboplatin chemotherapy, compared to chemotherapy alone, in patients with previously untreated metastatic triple-negative breast cancer.

This content is supported by Erytech.